Program Medium
Internet-based program
Method of Physician Participation Utilized in Learning Process
There are no fees for participating and receiving CME credit for this activity. During the period December 30, 2024 through December 30, 2026, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view the activity, totaling 2.5 hours, to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out CME certificate.
Estimated Time to Complete Educational Activity
2.5 hours. Physicians must study the enduring activity, and are expected to view every segment to successfully complete the activity and earn CME credit.
Course Overview
In this web-based program, physicians will learn how recent developments in novel targets and treatments have advanced the management of ovarian cancer and mucosal melanoma
Release Date
December 30, 2024
Expiration Date
December 30, 2026
Intended Audience
This complimentary CME educational activity is designed for all healthcare providers (HCPs) involved in developing, delivering, consulting, and monitoring care for patients with ovarian cancer or mucosal melanoma, including oncologists, gynecologists/gynecologic oncologists, dermatologists, dermatologic oncologists, and related clinicians.
Registration
Participation in this activity is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.
Grantor Support
This activity is supported by an independent medical education grant from Mural Oncology.
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Massachusetts Chan Medical School and CMEducation Resources, LLC. The University of Massachusetts Chan Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Massachusetts Chan Medical School, Office of Continuing Medical Education designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Policy on Faculty & Provider Disclosure
It is the policy of the University of Massachusetts Chan Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Chan Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.
Program Faculty and Disclosure
Richard Carvajal, MD
Deputy Physician-in-Chief and Director of Medical Oncology
Roy J. and Tara Zuckerberg Professor in Medical Oncology
Northwell Health Cancer Institute
Lake Success, NY
Consultant: Caper Labs, Castle Biosciences, Ideaya, Immunocore, Mural Oncology, TriSalus
Michael Lotze, MD
Professor of Surgery, Immunology, and Bioengineering
University of Pittsburgh Cancer Institute
University of Pittsburgh School of Medicine
Assistant Vice Chancellor, Sponsored Training Grants
University of Pittsburgh Schools of the Health Sciences
Pittsburgh, PA
Scientific Advisor/Advisory Board: Appel Sauce Studios, LLC, Alliance for Cancer Cell and Gene Therapy BioCytics, Inc, iRepertoire, Inc. KSQ,Inc. Ludwig Institute Miltenyi, Inc. Mural Oncology ZaiLab
John L. Hays, MD
Associate Professor, Department of Internal Medicine
Medical Director of the Clinical Trials Office
The Ohio State University College of Medicine
Wexner Medical Center & James Cancer Hospital
Columbus, OH
Consultant: Alkermes, Mersana, AstraZeneca, Merck, GOG Foundation, MJH Life Sciences, Curio Science LLC, Mural Oncology
Travel: Regeneron Inc
Ulka Vaishampayan, MBBS
Professor of Internal Medicine
Director, Phase I Program
Rogel Cancer Center
University of Michigan
Ann Arbor, MI
Speaker or Speaker’s Bureau: Bayer; Exelixis
Research Support: Merck; BMS
Consultant: Neurocrine Biosciences
Program Managers and Web Editor Disclosure
Program Managers Gideon Bosker, MD and Denise Leary have nothing to disclose.
Educational Objectives
Upon completion of this activity, participants will be able to:
Detail the disease burden, clinical presentation, and initial treatment options and immunotherapy-based treatments—including current and published trials and studies focused on novelly engineered IL-2 cytokine—for solid tumors including ovarian cancer and mucosal melanoma
Describe the potential side effects associated with immunotherapy, with a focus on mitigating side effects and improving effectiveness of IL-2-mediated treatment of solid tumors
Outline the scientific and translational aspects of cytokine science and its evolving role and potential as an immune-based therapy
Discuss the mechanism of action underling IL-2 therapy and how design variations of IL-2 can impact the safety and efficacy of IL-2; and be able to assess how re-engineered interleukins compare in their safety and efficacy profiles as compared to rhIL-2 and other variants
Outline the results of historical studies evaluating rhIL-2 therapy as support of proof-of-concept for its efficacy and how novel approaches to protein-engineered IL-2 alfa can build on this POC to support new IO-based approaches
Identify patient risk factors, signs & symptoms, diagnostic challenges, importance of accurate and early diagnosis, disease burden, guidelines-based therapy, unmet need, and emerging therapies for patients with mucosal melanoma (MM)
Identify patient risk factors, signs & symptoms, diagnostic challenges, importance of accurate and early diagnosis, disease burden, guidelines-based therapy, unmet need, and emerging therapies for patients with platinum-resistant ovarian carcinoma (PROC) and optimizing outcomes with therapeutic adherence
Hardware and Software Requirements:
To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.
Privacy Policy
When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:
Disclaimer
Copyright © 2024 by CMEducation Resources, LLC All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.
Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
